IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Linvoseltamab

"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Dickran Kazandjian, MD

OTHER